This site is intended for healthcare professionals outside the U.S.
Post-hoc analysis of pooled patient data from the phase IIb PSOR-005 and phase III ESTEEM® 1 and ESTEEM 2 studies. Among patients moderate to severe palmoplantar psoriasis (PPPGA score ≥3); was present in 144 patients (10.1%).
P = 0.021.
ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PPPGA, Palmoplantar Psoriasis Physician’s Global Assessment.
Reference: 1. Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99-105.
Please choose a country